Prialt Injection, Solution
Product Images NDC 70720-723

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Prialt (NDC 70720-723). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Tersera Therapeutics Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (Pri02 0000 01)

Chemical structure diagram showing the amino acid sequence of ziconotide acetate, the active ingredient in PRIALT injection, solution. The sequence is represented as a chain of amino acids with brackets indicating specific sub-sequences within the peptide.*

FDA Label Image

Figure 1 (Pri02 0000 02)

A bar chart comparing the percent of patients achieving various levels of percent improvement in pain from baseline after treatment with ziconotide versus placebo. The x-axis shows percent improvement increments from >0% to 100%, and the y-axis shows the corresponding percent of patients from 0% to 100%. Bars for ziconotide are higher than placebo at most improvement levels, indicating a greater proportion of patients experienced pain improvement with ziconotide.*

FDA Label Image

Principal Display Panel (20 mL Carton)

Carton label for PRIALT (ziconotide) intrathecal infusion injection, 500 mcg/20 mL (25 mcg/mL) sterile solution preservative-free. Label includes NDC 70720-723-10, storage instructions to keep refrigerated at 2-8°C and protect from light, and directions indicating use only with a microinfusion pump for intrathecal infusion. The label shows the product is distributed by TerSera Therapeutics LLC and references Medtronic SynchroMed II Infusion System compatibility.*

FDA Label Image

Principal Display Panel (1 mL Carton)

Carton label for PRIALT ziconotide intrathecal infusion injection, solution, 500 mcg/20 mL (25 mcg/mL), sterile preservative-free solution. The label states it is for intrathecal infusion only with a microinfusion pump and for pump priming, initial and maintenance dosing. Distributed by TerSera Therapeutics LLC. Includes storage instructions, NDC 70720-723-05, and usage with specific Medtronic infusion systems.*

FDA Label Image

Principal Display Panel (5 mL Carton)

Packaging label for PRIALT 100 mcg/mL intrathecal infusion injection solution. The label is for a sterile, preservative-free solution containing ziconotide acetate. It indicates use only with a microinfusion pump and includes storage instructions to keep refrigerated at 2-8°C and to protect from light. The labeler is TerSera Therapeutics LLC.*

FDA Label Image

Pri02 0000 06

PRIALT 500 mcg/5 mL intrathecal infusion solution label for ziconotide acetate injection. The sterile, preservative-free solution is indicated for intrathecal infusion only with a microinfusion pump, featuring warnings such as 'DO NOT USE for pump priming.' Distributed by TerSera Therapeutics LLC, the packaging includes storage instructions and the NDC 70720-722-10.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.